Resistance Training in Adults With Obesity

Overweight and Obesity Clinical Trial

Official title:

Acute and Chronic Effects of Two Different Types of Resistance Training on Cardiometabolic Health in Adults With Obesity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05092061
• Other study ID #: 246888
• Status: Completed
• Phase: N/A
• Start date: October 14, 2021
• Est. completion date: February 28, 2022

Study information

• Verified date: May 2022
• Source: Norwegian University of Science and Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this project is two-fold: (1) to assess if two different resistance training protocols elicit different responses in the acute phase and (2) to assess if the same two different protocols will elicit different long-term responses on muscular strength, body composition and cardiometabolic health. The project will include 30 adults with obesity (defined as BMI ≥ 30 or abdominal obesity according to the International Diabetes Federation). In the acute phase blood lactate, heart rate, enjoyment and perceived exertion will be assessed after the two resistance training protocols. In addition, the mean 24-h blood glucose concentration after exercise will be compared between the two protocols.

For the long-term effects blood markers of cardiometabolic health, blood pressure, body composition, objectively measured physical activity and physical fitness will be assessed before and after the intervention. Also, perceived health-related quality of life will be assessed before and after the intervention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: February 28, 2022
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Obesity (BMI = 30) or

• Central obesity (defined according to the International Diabetes Federation).

Exclusion Criteria:

• Unstable angina

• recent cardiac infarction (last 4 weeks)

• uncompensated heart failure

• severe valvular illness

• pulmonary disease

• uncontrolled hypertension

• kidney failure

• orthopaedic/neurological limitations

• cardiomyopathy

• planned operations during the research period

• participation in a parallel study

Related Conditions & MeSH terms

• Obesity
• Overweight
• Overweight and Obesity

Intervention

Other:
• Moderate-repetition resistance training
Will undertake resistance training with moderate loads, and moderate repetitions 3 times per week for 7 weeks.
• High-repetition resistance training
Will undertake resistance training with low loads, and high repetitions 3 times per week for 7 weeks.

Locations

Country	Name	City	State
Norway	Department of Circulation and Medical Imaging	Trondheim

Sponsors (1)

Lead Sponsor	Collaborator
Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glycated haemoglobin (HbA1c)		7 weeks
Secondary	Fasting glucose		7 weeks
Secondary	Blood lipid concentration		7 weeks
Secondary	C-reactive protein		7 weeks
Secondary	Systolic blood pressure		7 weeks
Secondary	Diastolic blood pressure		7 weeks
Secondary	Body fat	Measured by bioelectrical impedance (InBody 770)	7 weeks
Secondary	Fat-free mass	Measured by bioelectrical impedance (InBody 770)	7 weeks
Secondary	Body mass	Measured by bioelectrical impedance (InBody 770)	7 weeks
Secondary	Visceral fat area	Measured by bioelectrical impedance (InBody 770)	7 weeks
Secondary	Waist circumference		7 weeks
Secondary	VO2max (maximal aerobic capacity)		7 weeks
Secondary	Rate of force development	Measured by Kistler force plate	7 weeks
Secondary	Muscular strength (1RM)	Leg press and bench press	7 weeks
Secondary	Muscular endurance	Maximum number of repetitions using 50% of 1-RM	7 weeks
Secondary	Physical activity	Assessed at three timepoints throughout the intervention using SenseWear armband activity monitors and/or Personal Activity IntelligenceTM (using heart rate monitors and smart phone application).	Baseline (before intervention), 4 and 7 weeks.
Secondary	Health-Related Quality of Life	Using the Short-Form 36 survey and Satisfaction with Physical Function and Appearance Survey	7 weeks